ALX Oncology Holdings Inc Ordinary Shares ALXO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALXO is a good fit for your portfolio.
News
-
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
-
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
-
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
-
ALX Oncology shares jump 9% after Jefferies upgrade
Trading Information
- Previous Close Price
- $15.50
- Day Range
- $15.24–16.25
- 52-Week Range
- $3.94–17.42
- Bid/Ask
- $15.80 / $16.22
- Market Cap
- $819.09 Mil
- Volume/Avg
- 441,585 / 491,203
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 72
- Website
- https://www.alxoncology.com
Comparables
Valuation
|
Metric
|
ALXO
|
CLDX
|
RCUS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.27 | 4.82 | 2.52 |
Price/Sales | — | 260.58 | 9.76 |
Price/Cash Flow | — | — | — |
Price/Earnings
ALXO
CLDX
RCUS
Financial Strength
|
Metric
|
ALXO
|
CLDX
|
RCUS
|
|---|---|---|---|
Quick Ratio | 5.08 | 13.69 | 4.35 |
Current Ratio | 5.24 | 13.87 | 4.52 |
Interest Coverage | −108.56 | — | −170.00 |
Quick Ratio
ALXO
CLDX
RCUS
Profitability
|
Metric
|
ALXO
|
CLDX
|
RCUS
|
|---|---|---|---|
Return on Assets (Normalized) | −52.01% | −30.49% | −20.42% |
Return on Equity (Normalized) | −62.57% | −33.19% | −44.44% |
Return on Invested Capital (Normalized) | −63.49% | −32.85% | −49.53% |
Return on Assets
ALXO
CLDX
RCUS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nxnxlwzd | Zprj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mswykcm | Klgnsqt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zwbqtbhb | Nnrmh | $99.5 Bil | |
MRNA
| Moderna Inc | Bnfcngxkg | Pqxx | $38.8 Bil | |
ARGX
| argenx SE ADR | Jtjbshjb | Ktfwg | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Cfxdfmts | Fpvbc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cvjvlrlp | Wbltzzz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dthwpxbb | Kcbzsmf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Njdvrvfl | Xbpfyc | $12.5 Bil | |
INCY
| Incyte Corp | Pvznsly | Brtcxb | $11.6 Bil |